DCM
UTHR icon

Decatur Capital Management’s United Therapeutics UTHR Stock Holding History

Decatur Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-9,229
Closed -$2.65M – 43
2025
Q2 		$2.65M Hold
9,229
– – 1.16% 24
2025
Q1 		$2.85M Buy
9,229
+21
+0.2% +$7.2K 1.48% 21
2024
Q4 		$3.25M Buy
+9,208
New +$3.38M 1.48% 18

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Decatur Capital Management's UTHR Position: Q3 2025 in Review

Decatur Capital Management sold out of United Therapeutics (UTHR) in Q3 2025, closing a stake of 9,229 shares — an estimated $2.65M sold.

Decatur Capital Management first reported a position in UTHR in Q4 2024 and held it in 3 quarters. The position peaked at $3.25M in Q4 2024. 708 funds tracked by Wall St. Rank hold UTHR as of Q3 2025.

  • Decatur Capital Management reported no remaining United Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Decatur Capital Management sold 9,229 United Therapeutics shares in Q3 2025, an estimated $2.65M.
  • Decatur Capital Management first reported a position in United Therapeutics in Q4 2024 and held it in 3 quarters.
  • Decatur Capital Management's United Therapeutics position peaked at $3.25M in Q4 2024.
  • 708 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2025.

Based on Decatur Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.